Renal complex supplement may slow CKD progression in cats
Recent research has found the compound AB070597 had a positive impact on older felines' kidneys
Photo: Маргарита Гусева/Adobe Stock
The dietary renal complex supplement AB070597 may prevent the progression of chronic kidney disease (CKD) in cats, a new study found. Results of the study found that senior cats who were not given the AB070597 complex exhibited a significant rise in blood urea nitrogen (BUN), creatinine, and phosphorus levels compared to felines who did receive the supplement. The cats that received the supplement exhibited better overall kidney function compared to those that did not receive treatment.1
AB070597 is a patented compound of 6 amino acids and 1 peptide consisting of L-arginine, glycine, L-glutamine, L-histidine, L-aspartic acid, L-glutamic acid, and L-carnosine. The product is owned by Bio Health Solutions, a global manufacturer of kidney support products.
“I am excited to publish this research as it shows that the AB070597 complex has a reno-protective effect,” Sato Masahiko, DVM, PhD, DACVIM(SAIM), DAiCVIM(SAIM), coauthor of the study, published in the Journal of Feline Medicine and Surgery, said in a news release.2 “While further research is needed to fully understand the reno-protective effects of AB070597, it shows promise as a valuable addition to supporting renal health in aging cats."
The prospective, randomized, controlled parallel-group study looked at 35 cats with CKD. Participants were randomly assigned to receive either 300 mg of AB070597 orally or a placebo for a period of 180 days; 20 were given AB070597 while 15 received the placebo. Throughout the study, the cats were reevaluated every 30 days. Researchers compared the results from the beginning of the study to the end for both groups to determine how effective AB070597 was in treating cats with CKD.
In the placebo group, BUN, creatinine, and phosphorus levels significantly increased at the 180-day mark compared to the group’s baseline, 30-day, and 60-day levels. In the group receiving AB070597 however, these levels were not significantly changed. Additionally, the International Renal Interest Society (IRIS) stage of kidney disease in cats administered AB070597 remained stable from the beginning to the end of the study, while 26% of the placebo group progressed from stage 2 to stage 3 of IRIS. There were no significant changes in body weight for either group, according to the study’s authors.1
“At Bio Health Solutions, our mission is to help pets live longer, healthier, and happier lives,” Mark Garrison, CEO of Bio Health Solution, said in a company release.2 “As a leader in pet renal health, I am humbled to have a key opinion leader like Dr Sato reconfirm the efficacy of our AB070597 complex. We believe all senior pets and those at risk for renal issues need multimodal support that logically would include ABO70597, as a direct renal support complex.”
References
- Tsunekawa N, Sato M. Efficacy of oral AB070597 for the management of chronic kidney disease in cats: A prospective, randomised, controlled parallel-group study. Journal of Feline Medicine and Surgery. 2024;26(10). https://doi.org/10.1177/1098612X241275249
- Bio Health Solutions announces newly published research for supporting renal health in cats. News release. Bio Health Solutions. November 15, 2024. Accessed November 20, 2024. [email]
